1. Kinnaird A, Yerram NK, O’Connor L, Brisbane W, Sharma V, Chuang R, Jayadevan R, Ahdoot M, Daneshvar M, Priester A, Delfin M, Tran E, Barsa DE, Sisk A, Reiter RE, Felker E, Raman S, Kwan L, Choyke PL, Merino MJ, Wood BJ, Turkbey B, Pinto PA, Marks LS. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer. J Urol. 2022 Apr;207(4):823-831. doi: 10.1097/JU.0000000000002343. Epub 2021 Dec 2. PMID: 34854746.
2. Daneshvar M, Pinto PA. Ablation of Low-Risk Prostate Cancer: Both Sides of the Story. J Endourol. 2021 Sep;35(9):1288-1289. doi: 10.1089/end.2021.0530. PMID: 34210164.
Here we discuss whether or not focal therapy should be utilized in low risk prostate cancer. We currently have some data on its utility in intermediate risk prostate cancer. Further studies and trials are being conducted to answer this question.
3. Williams C, Ahdoot M, Daneshvar MA, Hague C, Wilbur AR, Gomella PT, Shih J, Khondakar N, Yerram N, Mehralivand S, Gurram S, Siddiqui M, Pinsky P, Parnes H, Merino M, Wood B, Turkbey B, Pinto PA. Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer? J Urol. 2022 Jan;207(1):95-107. doi: 10.1097/JU. 0000000000002182. Epub 2021 Aug 26. PMID: 34433302; PMCID: PMC8665000.
Here we delve into prostate cancer imaging characteristics with the hope of identifying lesions on MRI that can be ‘invisible’ and finding reasons that these lesions can be missed on biopsy.
4. Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, Rathmell WK, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer. 2021 Aug 3. doi: 10.1002/cncr.33679. Epub ahead of print. PMID: 34343338.
As part of an international panel, we identified specific patients and scenarios where genetic risk assessment for kidney cancer should be performed. This was the first genetic risk assessment consensus that was performed. Stay tuned, there will be a follow up panel and consensus Fall ’22.
5. Leong JY, Pinkhasov R, Chandrasekar T, Shapiro O, Daneshvar M, Jacob J, Sanford T, Bratslavsky G, Goldberg H. Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey. Eur Urol Focus. 2021 Jul 28:S2405-4569(21)00189-9. doi: 10.1016/j.euf.2021.07.009. Epub ahead of print. PMID: 34332951.
6. Webster BR, Rompre-Brodeur A, Daneshvar M, Pahwa R, Srinivasan R. Kidney cancer: from genes to therapy. Curr Probl Cancer. 2021 Jul 3:100773. doi: 10.1016/j.currproblcancer.2021.100773. Epub ahead of print. PMID: 34261604.
7. Bratslavsky G, Sokol ES, Daneshvar M, Necchi A, Shapiro O, Jacob J, Liu N, Sanford TS, Pinkhasov R, Goldberg H, Killian JK, Ramkissoon S, Severson EA, Huang RSP, Danziger N, Mollapour M, Ross JS, Pacak K. Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers (Basel). 2021 Jul 1;13(13):3312. doi: 10.3390/cancers13133312. PMID: 34282751; PMCID: PMC8268679.
8. Khondakar NR, Owens-Walton J, Daneshvar M, Williams C, O’Connor L, Yerram NK, Pinto PA. Emerging role for local therapy in oligometastatic prostate cancer. Clin Adv Hematol Oncol. 2021 Jul;19(7):460-467. PMID: 34236345.
9. O’Connor L, Ramedani S, Daneshvar M, George A, Luis Abreu A, Cacciamani G, Lebastchi A. Future perspective of focal therapy for localized prostate cancer. Asian Journal of Urology. 2021. – Pending print
10. Williams C, Khondakar NR, Daneshvar MA, O’Connor LP, Gomella PT, Mehralivand S, Yerram NK, Egan J, Gurram S, Rompré-Brodeur A, Webster BR, Owens-Walton J, Parnes H, Merino MJ, Wood BJ, Choyke P, Turkbey B, Pinto PA. The Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by Combined MRI-Fusion and Systematic Biopsy. J Urol. 2021 Jun 28:101097JU0000000000001941. doi: 10.1097/JU.0000000000001941. Epub ahead of print. PMID: 34181465.
11. Williams C, Daneshvar M, Pinto P. Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer. Curr Opin Oncol. 2021 May 1;33(3):244-251. doi: 10.1097/CCO.0000000000000717. PMID: 33606404.
12. Ahdoot M, Lebastchi AH, Long L, Wilbur AR, Gomella PT, Mehralivand S, Daneshvar M, Yerram NK, O’Connor LP, Wang AZ, Gurram S, Bloom J, Siddiqui MM, Linehan WM, Merino M, Choyke PL, Pinsky P, Parnes H, Shih JH, Turkbey B, Wood BJ, Pinto PA; Trio Study Group. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. Eur Urol Oncol. 2021 Apr 10:S2588-9311(21)00048-1. doi: 10.1016/j.euo.2021.03.004. Epub ahead of print. PMID: 33846112.
13. Bloom JB*, Daneshvar M*, Lebastchi AH, Ahdoot M, Gold SA, Hale G, Mehralivand S, Sanford T, Valera V, Wood BJ, Choyke PL, Merino MJ, Turkbey B, Parnes HL, Pinto PA. Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients. Urol Oncol. 2021 Mar 15:S1078-1439(21)00080-6. doi: 10.1016/j.urolonc.2021.02.018. Epub ahead of print. PMID: 33736975. *Denotes equal contribution.
14. O’Connor LP, Lebastchi AH, Fasaye GA, Dikoglu E, Daneshvar M, Ahdoot M, Merino MJ, Pinto PA. ‘Case of the Month’ from the National Cancer Institute, Bethesda, MD, USA: investigating genetic aberrations in a patient with high-risk prostate cancer. BJU Int. 2021 Feb;127(2): 171-174. doi: 10.1111/bju.15273. PMID: 33547722.
